Cognoa preps FDA filing for digital autism diagnostic
pharmaphorum
SEPTEMBER 24, 2020
An artificial intelligence-powered diagnostic for autism spectrum disorder (ASD), developed by Cognoa, has met all its objectives in a pivotal trial and will be filed for approval with the FDA. It’s reported that parents can often spot the early signs of developmental problems within 18 months.
134 
Let's personalize your content